Market capitalization | $1.43b |
Enterprise Value | $1.23b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.15 |
P/S ratio (TTM) P/S ratio | 4.81 |
P/B ratio (TTM) P/B ratio | 5.39 |
Revenue growth (TTM) Revenue growth | -3.95% |
Revenue (TTM) Revenue | $297.08m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
9 Analysts have issued a CareDx, Inc. forecast:
9 Analysts have issued a CareDx, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 297 297 |
4%
4%
|
|
Gross Profit | 191 191 |
3%
3%
|
|
EBITDA | -58 -58 |
17%
17%
|
EBIT (Operating Income) EBIT | -76 -76 |
13%
13%
|
Net Profit | -160 -160 |
90%
90%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
CareDx, Inc. operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
Head office | United States |
CEO | John Hanna |
Employees | 643 |
Founded | 1998 |
Website | www.caredx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.